OCS
Oculis Holding AG$14.51
LiveJun 01, 2026
Market cap
$829.53M
52w range
13.81 – 34.48
P / E
—
EPS
—
Volume
6.66M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Oculis Holding AG’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for OCS.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -36.09% | -51.52% | -47.20% | -50.66% | -23.63% | -27.34% | -24.51% | +31.91% | +49.43% | +49.59% | +49.59% |
Aftermarket
LiveLast trade
$14.50
130 sh
Bid
$14.40
5 sh
Ask
$14.51
802 sh
Spread
$0.110
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Biotechnology-2.72%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $39.40 (+171.54%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Oculis Reports Q1 2026 Financial Results and Provides Company Updateglobenewswire.com·May 11, 2026
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trialglobenewswire.com·May 07, 2026
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trialglobenewswire.com·May 07, 2026
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meetingglobenewswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|